Ministry of Health targets 70% local medicine production

The Ministry of Health has announced an ambitious goal to increase Ghana's local medicine production capacity from the current 30% to 70%. This initiative is designed to bolster national health security and mitigate the risks associated with the country's heavy reliance on imported pharmaceutical products. Speaking at the Annual General Meeting of the West African Postgraduate College of Pharmacists (WAPCP) Ghana Chapter, Dr. Hafez Adam Taher, representing the Minister of Health, emphasized that the shift is essential to protecting the population from global supply chain disruptions. Currently, Ghana imports over 70% of its medicines, a situation that officials describe as a significant risk to the health system.

To address these vulnerabilities, the government is planning to establish a pharmaceutical innovation park. This facility is intended to provide a specialized hub for manufacturers, offering shared resources and research capabilities to help domestic firms scale up their operations. By centralizing resources and expertise, the Ministry hopes to foster a more competitive pharmaceutical environment that can produce high-quality medications for the local and regional markets. The innovation park is a key pillar in the broader strategy to transform Ghana into a regional hub for pharmaceutical excellence.

However, achieving the 70% target will require significant capital investment and the introduction of new financing models. Industry leaders at the WAPCP meeting stressed the need for improved access to credit to allow manufacturers to expand their facilities and diversify their product lines. Moving beyond basic medications, the vision includes the production of more complex pharmaceuticals, such as vaccines, which would further solidify Ghana's healthcare independence. Stakeholders argued that dedicated financial support is a critical component for the transition from a 30% to 70% domestic manufacturing capacity.

The successful realization of this production target is expected to stabilize the supply of essential drugs and potentially lower costs for consumers across the country. By supporting the growth of the domestic pharmaceutical industry, the government aims to create a more resilient health system that is less dependent on external factors. Moving forward, the successful implementation of the innovation park and the securing of sustainable financing for manufacturers will be the primary benchmarks for achieving the nation's goal of pharmaceutical self-sufficiency.